Imunon, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Imunon, Inc. (Nasdaq: IMNN) on January 7, 2026. The report discloses significant changes in executive leadership regarding the Chief Financial Officer role, effective January 14, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Interim CFO Retainer: $30,000 per month for Jeffrey Church.
- Additional Compensation: $250 per hour for services exceeding 40 hours per month.
Material Changes
The primary material change is the departure of Kimberly Graper as Interim Chief Financial Officer and the appointment of Jeffrey Church to the same role.
- Resignation: Kimberly Graper is resigning to pursue another career opportunity. There are no disagreements with management.
- Appointment: Jeffrey Church, a former Executive Vice President and CFO who retired in May 2024, is returning as Interim CFO and Principal Accounting Officer.
- Agreement Amendment: The Company amended Mr. Church's existing consulting agreement to formalize the retainer and hourly rates effective January 14, 2026.
Outlook, Risks, and Management Commentary
CEO Stacy Lindborg stated that the Company thanks Ms. Graper for her contributions over the past three years and wishes her well. Management indicated that Ms. Graper's notice provides sufficient time for a smooth transition. The filing notes that Mr. Church's selection was not pursuant to any arrangement with other persons and that he has no material interest in transactions requiring disclosure under Item 404(a).
Investor Verification Checklist
- Verify the effective date of the leadership transition (January 14, 2026).
- Review the full text of the Retirement and Consulting Agreement (Exhibit 10.1) for termination clauses and total potential liability.
- Confirm the status of the Company's search for a permanent Chief Financial Officer.
- Check subsequent filings for any impact on the Company's financial reporting timeline due to the interim appointment.